Venous thromboembolism in Latin America: a review and guide to diagnosis and treatment for primary care

Ceresetto, José

doi:10.6061/clinics/2016(01)07

Cited by 18 publications

(20 citation statements)

References 81 publications

(90 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…VTEs are thus not routinely considered as a priority differential in most African countries by physicians when approaching pregnant women with acute abdominal pain. Consequently, VTEs in pregnancy in low and middle income countries are more likely to be missed [10]. The epidemiological and clinical burdens of VTEs in pregnancy in the African context may be grossly underestimated because of under/misdiagnosis and possibly an associated high case fatality rate particularly in sub-urban areas.…”

Section: Resultsmentioning

confidence: 99%

Right iliac vein thrombosis mimicking acute appendicitis in pregnancy: a case report

Aroke

Kadia²,

Dimala

et al. 2017

BMC Res Notes

View full text Add to dashboard Cite

BackgroundRight iliac vein thrombosis is uncommon in pregnancy. Nonetheless, when it does occur, its presentation could be very unspecific with important diagnostic challenges and this could have negative therapeutic consequences especially in a resource limited setting.Case presentationThe historical, clinical and laboratory data of a 30 year old G2P1001 woman of African ethnicity at 11 weeks of gestation pointed towards a right iliac vein thrombosis missed for an acute appendicitis with subsequent appendectomy and failure to cure. Following the diagnosis of right iliac vein thrombosis post-appendectomy, the patient was started on low molecular weight heparin and the clinical progress thereafter was favourable.ConclusionPelvic vein thrombosis should be considered a differential diagnosis of intractable lower abdominal pain in early pregnancy. A high index of suspicion could lead to early diagnosis, prompt management and a favourable prognosis even in a low-income setting.

show abstract

Section: Resultsmentioning

confidence: 99%

Right iliac vein thrombosis mimicking acute appendicitis in pregnancy: a case report

Aroke

Kadia²,

Dimala

et al. 2017

BMC Res Notes

View full text Add to dashboard Cite

show abstract

“…The guidelines for individual countries in Latin America are generally consistent with those of the American College of Chest Physicians and other American and European guidelines. 2 Given its positive results in CAT management, DOACs has already been incorporated in these guidelines, such as the recent Scientific and Standardization Committee recommendations for the International Society of Thrombosis and Hemostasis and the National Comprehensive Cancer Network, both in 2018. 32,33 Latin America guidelines will probably incorporate these recommendations.…”

Section: Final Considerationsmentioning

confidence: 99%

Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide

Ramacciotti

Aguiar²,

Júnior

et al. 2018

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use in the treatment of venous thromboembolism (VTE) in Latin America, following global approvals for this indication. Edoxaban features some particular characteristics when compared to the previously approved DOACs. This review summarizes the main properties of edoxaban, the outcomes results of its pivotal global clinical trials and the peculiar clinical features of this compound. This practical guide aims to help Latin America clinicians understand edoxaban, its proper indication and its use for the appropriate patients with VTE.

show abstract

“…18 Pulmonary thromboembolism can be classified as low risk (normotensive, without RV failure), moderate risk (normotensive, with RV failure), or high risk (refractory hypotension). 19,20 While practical, this classification involves problems related to the definition of RV failure, whether by dilatation or dysfunction, based on unclear and subjective criteria and linked with an inability to accurately predict its morbidity and mortality. [20][21][22] This reveals a need to evaluate more trustworthy markers of severity to contribute to treatment decisions.…”

Section: Risk Stratification In Ptementioning

confidence: 99%

Terapia fibrinolítica sistêmica no tromboembolismo pulmonar

Ceresetto

Marques

2017

J. vasc. bras.

View full text Add to dashboard Cite

Pulmonary thromboembolism remains a major therapeutic challenge for specialists and, despite investment and the consequent developments in diagnosis, prophylaxis, and treatment, the condition is still the leading cause of avoidable deaths in hospital settings. There is still great uncertainty with relation to the profile of patients who will actually benefit from systemic fibrinolytic treatment, without being exposed to serious risk of bleeding. There are tools that can help to identify patients who will benefit, including risk stratification and estimation of the prognosis of the event, with clinical scores for right ventricular failure, markers of right ventricular dysfunction and dilatation, and thrombotic mass assessment, whether alone or in combination. The only points of consensus with relation to fibrinolytic therapy for treatment of pulmonary thromboembolism are as follows: it should not be routinely indicated, none of the scores or markers alone should be used to justify its use, and patients with hemodynamic instability are the most likely to benefit. Furthermore, each case should be evaluated for risk of bleeding, especially central nervous system bleeding.Keywords: fibrinolytics; pulmonary embolism; hemorrhage. ResumoO tromboembolismo pulmonar permanece como um grande desafio terapêutico para os médicos especialistas, pois, apesar de todo investimento e desenvolvimento em seu diagnóstico, profilaxia e tratamento, essa condição continua sendo a principal causa de morte evitável em ambiente hospitalar. Ainda restam muitas dúvidas em relação a qual perfil de paciente vai se beneficiar de fato da terapia fibrinolítica sistêmica, sem ficar exposto a um grande risco de sangramento. A estratificação de risco e a avaliação do prognóstico do evento, através de escores clínicos de insuficiência ventricular direita, marcadores de dilatação e disfunção do ventrículo direito e avaliação da massa trombótica, associados ou de forma isolada, são ferramentas que podem auxiliar na identificação do paciente que irá se beneficiar dessa terapia. Os únicos consensos em relação à terapia fibrinolítica no tratamento do tromboembolismo pulmonar são: não deve ser indicada de forma rotineira; nenhum dos escores ou marcadores, isoladamente, devem justificar seu uso; e os pacientes com instabilidade hemodinâmica são os mais beneficiados. Além disto, deve-se avaliar cada caso em relação ao risco de sangramento, especialmente no sistema nervoso central.Palavras-chave: fibrinolíticos; embolia pulmonar; hemorragia.

show abstract

Venous thromboembolism in Latin America: a review and guide to diagnosis and treatment for primary care

Cited by 18 publications

References 81 publications

Right iliac vein thrombosis mimicking acute appendicitis in pregnancy: a case report

Right iliac vein thrombosis mimicking acute appendicitis in pregnancy: a case report

Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide

Terapia fibrinolítica sistêmica no tromboembolismo pulmonar

Contact Info

Product

Resources

About